(hereinafter referred to as OR CRO[insert acting in its own name name of CRO] “Sponsor”) and for and on behalf of [insert trial registered office is at [insert name of Sponsor], address of (hereinafter referred to as CRO] “CRO”) and [insert trial address is at [insert lawfully represented by [insert name of institution], address], name(s) and function(s)] (hereinafter referred to as “Institution”) [N.B. In case the specialistisch bedrijf” will cosign the agreement, the following text can be “medisch used for the Institution:] [Name located at [adress], The Netherlands, lawfully represented by [name “ of the hospital], and (hereinafter referred to as and function] “[name of hospital]”; [name located at [adress], The Netherlands, lawfully represented by of medisch specialistisch bedrijf], [name (hereinafter referred to as and function] “[name of MSB]”; (hereinafter [name and [name jointly referred to as of hospital] of MSB] “Institution”)” [In case the Principal Investigator is not an employee of Institution and acts as a party:] and [INVESTIGATOR], [insert: name of physician [tax/office address and chamber of …», …[function], commerce registration number, if applicable] (hereinafter referred to as ] Investigator”) “Principal [ OR in case the Principal Investigator is an employee of the Institution: ] in the presence of [INVESTIGATOR] [insert investigator’s title, name and department of Institution where the the supervisor under whose responsibility the conduct of the Clinical Trial investigator is employed], will be carried out (hereinafter referred to as Principal Investigator”) “the WHEREAS, the Sponsor is a pharmaceutical company involved in research, development, registration, manufacture and/or sale of medicines for use in humans; WHEREAS, the Sponsor has designed the Clinical Trial identified hereof, to evaluate Sponsor’s drug [insert (“Study in accordance with the Protocol defined below; and Drug”) study drug(s)]
(hereinafter referred to as “Sponsor”) OR CRO[insert name of CRO] acting in its own name and for and on behalf of [insert name of Sponsor], registered office is at [insert address of CRO] (hereinafter referred to as “CRO”) and [insert name of institution], address is at [insert address], lawfully represented by [insert name(s) and function(s)] (hereinafter referred to as “Institution”) [N.B. In case the “medisch specialistisch bedrijf” will cosign the agreement, the following text can be used for the Institution:] “ [Name of the hospital], located at [adress], The Netherlands, lawfully represented by [name and function] (hereinafter referred to as “[name of hospital]”; and [name of medisch specialistisch bedrijf], located at [adress], The Netherlands, lawfully represented by [name and function] (hereinafter referred to as “[name of MSB]”; (hereinafter [name of hospital] and [name of MSB] jointly referred to as “Institution”)” [In case the Principal Investigator is not an employee of Institution and acts as a party:] and [INVESTIGATOR], [insert: name of physician …», …[function], [tax/office address and chamber of commerce registration number, if applicable] (hereinafter referred to as “Principal Investigator”) ] [ OR in case the Principal Investigator is an employee of the Institution: ] in the presence of [INVESTIGATOR] [insert investigator’s title, name and department of Institution where the investigator is employed], the supervisor under whose responsibility the conduct of the Clinical Trial will be carried out (hereinafter referred to as “the Principal Investigator”) WHEREAS, the Sponsor is a pharmaceutical company involved in research, development, registration, manufacture and/or sale of medicines for use in humans; WHEREAS, the Sponsor has designed the Clinical Trial identified hereof, to evaluate Sponsor’s drug [insert study drug(s)] (“Study Drug”) in accordance with the Protocol defined below; and trial trial
Template-CTA-NefarmaNFUSTZAcronNKI-7July2016-FINAL-8-juli-2016-1.docx